BSN Tracker

desvenlafaxine

Brand: Pristiq, Khedezla

⚠ BBW Prototype: venlafaxine
Drug Class: SNRI
Drug Family: antidepressant
Subclass: serotonin-norepinephrine reuptake inhibitor
Organ Systems: cns

Mechanism of Action

Active O-desmethyl metabolite of venlafaxine that inhibits both serotonin and norepinephrine transporters. Unlike venlafaxine, it requires no hepatic activation and has minimal CYP enzyme interactions, offering a more predictable pharmacokinetic profile.

SERT (serotonin transporter)NET (norepinephrine transporter)

Indications

  • major depressive disorder
  • off-label: vasomotor symptoms of menopause
  • off-label: fibromyalgia

Contraindications

  • concurrent MAOI use
  • uncontrolled narrow-angle glaucoma

Adverse Effects

Common

  • nausea
  • headache
  • dizziness
  • insomnia
  • dry mouth
  • constipation
  • diaphoresis
  • sexual dysfunction

Serious

  • hypertension (dose-dependent)
  • serotonin syndrome
  • suicidal ideation
  • discontinuation syndrome
  • hyponatremia

Pharmacokinetics (ADME)

Absorption well absorbed orally; bioavailability ~80%; food has no significant effect on absorption
Distribution protein binding ~30%; Vd ~3.4 L/kg
Metabolism primarily conjugation (glucuronidation); minimal CYP involvement; not a significant CYP inhibitor or inducer
Excretion renal (~45% unchanged); dose adjustment required if CrCl <50 mL/min
Half-life 11 hours
Onset 1-4 weeks for antidepressant effect
Peak 7.5 hours
Duration 24 hours
Protein Binding 30%
Vd 3.4 L/kg

Drug Interactions

Drug / Agent Mechanism Severity
MAOIs serotonin syndrome contraindicated
linezolid serotonin syndrome risk major
NSAIDs/aspirin increased bleeding risk via serotonin-mediated platelet dysfunction moderate

Nursing Considerations

  1. Monitor blood pressure at baseline and after each dose increase; noradrenergic activity causes dose-dependent hypertension — particularly relevant at doses >50 mg/day.
  2. Desvenlafaxine requires no hepatic activation (unlike venlafaxine), making it predictable in patients with CYP2D6 polymorphisms or hepatic impairment.
  3. Taper dose gradually over at least 2 weeks on discontinuation; abrupt stopping causes dizziness, insomnia, nausea, and sensory disturbances.
  4. Dose reduction required in severe renal impairment (CrCl <30 mL/min: 50 mg every other day); monitor renal function in patients with CKD.

Clinical Pearls

  • As the active metabolite of venlafaxine, desvenlafaxine offers a more predictable pharmacokinetic profile independent of CYP2D6 metabolizer status, making it useful in patients who are poor CYP2D6 metabolizers or on CYP2D6 inhibitors.
  • Its off-label use for vasomotor symptoms of menopause is supported by multiple RCTs, providing a non-hormonal option for women who cannot use estrogen.

Safety Profile

Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Major Depressive Disorder Off-label: Fibromyalgia Off-label: Vasomotor Symptoms Of Menopause SNRI
← Back to Medications